We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cell Signaling Technology Announces Continued PhosphoScan® Proteomics Research Project with Bristol-Myers Squibb
News

Cell Signaling Technology Announces Continued PhosphoScan® Proteomics Research Project with Bristol-Myers Squibb

Cell Signaling Technology Announces Continued PhosphoScan® Proteomics Research Project with Bristol-Myers Squibb
News

Cell Signaling Technology Announces Continued PhosphoScan® Proteomics Research Project with Bristol-Myers Squibb

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cell Signaling Technology Announces Continued PhosphoScan® Proteomics Research Project with Bristol-Myers Squibb"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cell Signaling Technology, Inc. (CST) announced the continuation of a research agreement with Bristol-Myers Squibb Company under which CST will employ its patented PhosphoScan® technology in the cell and tumor phospho-profiling of a Bristol-Myers Squibb small-molecule kinase inhibitor.

The PhosphoScan® profiling research project builds on a successful evaluation project between the two companies, which was completed in March 2007, and will involve in vivo phosphorylation profiling of kinase inhibitor response profiles in xenograft tumor models.

PhosphoScan® proteomics is a patented strategy for broad profiling of phosphorylation in cells and tissues. The PhosphoSignatures™ generated with the Bristol-Myers Squibb compound will be analyzed and understood within the context of CST’s PhosphoSignature™ database covering hundreds of cancer cell lines and human tumors.

PhosphoScan® profiling involves immunoaffinity purification and tandem mass spectroscopy and its effectiveness in kinase target and biomarker discover in cancer was illustrated most recently in the journal Cell.

“Our PhosphoScan® profiling research with Bristol-Myers Squibb has been very successful and we are glad to have the opportunity to extend that research in analysis of Bristol-Myers Squibb’s kinase inhibitors in tumor models,” said Christopher Bunker, CST’s Director of Business Development.

Dr. Bunker went on to say, “The application of PhosphoScan® to both cell and tumor models is an effective strategy by which to validate PhosphoSignature™ discoveries enabling the opportunity to develop biomarker assays specific for Bristol-Myers Squibb targeted small molecule therapeutics.”

Advertisement